Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Non-Current Debt (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Non-Current Debt for 15 consecutive years, with $34.3 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-Current Debt fell 2.89% to $34.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $34.3 million, a 2.89% decrease, with the full-year FY2023 number at $30.7 million, down 28.62% from a year prior.
  • Non-Current Debt was $34.3 million for Q3 2024 at Harvard Bioscience, up from $32.0 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $46.5 million in Q3 2022 to a low of $30.7 million in Q4 2023.
  • A 5-year average of $40.5 million and a median of $41.1 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: soared 1257.0% in 2020, then decreased 28.62% in 2023.
  • Harvard Bioscience's Non-Current Debt stood at $46.3 million in 2020, then dropped by 2.57% to $45.1 million in 2021, then decreased by 4.62% to $43.0 million in 2022, then fell by 28.62% to $30.7 million in 2023, then increased by 11.56% to $34.3 million in 2024.
  • Per Business Quant, the three most recent readings for HBIO's Non-Current Debt are $34.3 million (Q3 2024), $32.0 million (Q2 2024), and $31.9 million (Q1 2024).